We tested, and confirmed, that Olink® PEA technology is indeed compatible with non-human primate (NHP) plasma. By comparing results from NHP plasma samples to those from human plasma samples run on Olink Explore 3072, we found that that the majority of our protein assays performed just as well in NHP samples as for human plasma samples and passed our rigorous assay quality control measures. These results show that Olink technology presents another means for translational studies and the development of therapeutics and vaccines using NHPs.
NHPs are commonly suggested as the animal model in preclinical and translational studies where developing therapeutics using rodents have failed or in studies aiming to improve vaccines and therapies. Due to the great similarity between the genome and exome of humans and different NHP species, antibodies targeting human proteins should feasibly detect those of NHPs. We therefore sought to examine the detectability and compatibility of NHP plasma proteins with Olink PEA technology.
The inflammation-related study used Olink Explore 3072 to analyze plasma samples from macaques comprising four treatment groups and a control group. The quality metrics of this analysis, together with results on protein detectability, were compared to data generated in another study on human plasma samples analyzed on the same platform.
